Suggestions will update as you type

About Inluriyo

Inluriyo is a targeted* oral treatment for ER+, HER2–, ESR1-mutated metastatic breast cancer (MBC).

Woman with short hair looking into camera.
Actor portrayal.

Approved for ER+, HER2–, ESR1-mutated MBC that progressed after endocrine therapy.

Inluriyo is an oral prescription medication that is approved for adults with ER+, HER2–, ESR1-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic) whose cancer was previously treated with endocrine therapy.

*Inluriyo affects healthy cells and breast cancer cells, which can result in side effects, some of which can be serious.

Inluriyo is a targeted treatment for ER+, HER2–, ESR1-mutated MBC.

Some breast cancers have an ESR1 mutation that leads to overactive estrogen receptors that fuel the growth and division of cancer cells. Inluriyo binds to and blocks these overactive estrogen receptors, slowing the growth of breast cancer cells.

Select Safety Information

Inluriyo may cause serious side effects. Inluriyo can harm your unborn baby. Women who are able to become pregnant and males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment with Inluriyo and for 1 week after the last dose of Inluriyo. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Inluriyo. Do not breastfeed during treatment with Inluriyo and for 1 week after the last dose.

Inluriyo may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

ER+=estrogen receptor-positive; ESR1=estrogen receptor-1; HER2–=human epidermal growth factor receptor 2-negative.

Learn about Inluriyo as a treatment option for ER+, HER2–, ESR1-mutated MBC.

If your metastatic breast cancer has an ESR1 mutation, Inluriyo may be an option for you.

INDICATION

Inluriyo™ (en-loo-ree-yoh) is a prescription medicine used to treat adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has progressed after at least 1 line of endocrine therapy.

Your healthcare provider will perform a test to make sure that Inluriyo is right for you.

It is not known if Inluriyo is safe and effective in children.

SAFETY SUMMARY

Before taking Inluriyo, tell your healthcare provider about all your medical conditions, including if you:

  • Have liver problems.
  • Are pregnant or plan to become pregnant. Inluriyo can harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if Inluriyo passes into breastmilk. Do not breastfeed during treatment with Inluriyo and for 1 week after the last dose.

Females who are able to become pregnant:

  • Your healthcare provider will do a pregnancy test before you start treatment with Inluriyo.
  • Use effective birth control (contraception) during treatment with Inluriyo and for 1 week after the last dose.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Inluriyo.

Males with female partners who are able to become pregnant:

  • Use effective birth control (contraception) during treatment with Inluriyo and for 1 week after the last dose.

Most common side effects of Inluriyo include decreased hemoglobin (anemia), muscle and joint pain, decreased white blood cell counts, increased liver function tests, decreased calcium blood levels, tiredness, diarrhea, increased triglyceride and cholesterol blood levels, nausea, decreased platelet counts, constipation, and stomach-area (abdominal) pain. These are not all the possible side effects of Inluriyo.

Your healthcare provider will check your blood levels, including monitoring your triglyceride and cholesterol blood levels, before and during treatment with Inluriyo.

Your healthcare provider may change your dose, temporarily stop, or completely stop Inluriyo if you develop certain side effects.

Inluriyo may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Inluriyo and other medicines may affect each other, causing side effects. Keep a list of your current medications, vitamins, and supplements to show your healthcare provider or pharmacist when you get a new medicine.

How to take Inluriyo
Take Inluriyo exactly as your healthcare provider tells you.

  • Your healthcare provider may change or stop your dose if needed. Do not stop taking Inluriyo or change the dose unless instructed to do so by your healthcare provider.
  • Take Inluriyo once daily, at approximately the same time each day.
  • Take on an empty stomach, at least 2 hours before food or 1 hour after food.
    • Swallow Inluriyo tablets whole. Do not chew, crush, or split the tablets.
  • If you miss a dose by 6 hours or more or vomit after taking Inluriyo, do not take another dose on that day. Take your next dose the following day at your regularly scheduled time.

Learn more
Inluriyo is a prescription medicine available as 200 mg tablets. For more information, call 1-800-545-5979.

This summary provides basic information about Inluriyo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Inluriyo and how to take it. Your healthcare provider is the best person to help you decide if Inluriyo is right for you.

IN CON BS M APP
Inluriyo™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.